Safety of oral bisphosphonates: Controlled studies on alveolar bone

International Journal of Oral and Maxillofacial Implants

Volumn 21, Issue 3, 2006, Pages 349-353

  Jeffcoat, Marjorie K ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Alveolar bone; Bisphosphonates; Clinical trials; Implants; Periodontal disease; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; HUMAN; JAW DISEASE; MALE; MIDDLE AGED; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; TOOTH IMPLANTATION;

ADULT; AGED; ALVEOLAR BONE LOSS; BONE DENSITY CONSERVATION AGENTS; DENTAL IMPLANTATION, ENDOSSEOUS; DIPHOSPHONATES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS;

EID: 33745489614     PISSN: 08822786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: Dept of Health and Human Services, 2004.
2. Jeffcoat MK. Osteoporosis and oral bone loss: Current literature. J Periodontol (in press).
3. Arneson TJ, Melton LJ III, Lewallen DG, O'Fallon WM. Epidemiology of diaphyseal and distal femoral fractures in Rochester, Minnesota, 1965-1984. Clin Orthop 1988;234:188-194.
4. Cooper C, Melton LJ III. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J (eds). Osteoporosis. San Diego, CA: Academic Press, 1996:419-434.
5. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
6. Ruggiero SL, Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2003;61:1238-1239.
8. Schwartz HC. Osteonecrosis and bisphosphonates: Correlation versus causation. J Oral Maxillofac Surg 2004;62:763-764.
9. Viale PH, Lin A. Exposed bone in oral cavities. Clin J Oncol Nurs 2005;9:355-357.
10. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24(6):45-52.
11. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:15-20.
12. Markiewicz MR, Margarone JE III, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: A review of current knowledge. J Am Dent Assoc 2005;136:1669-1674.
13. Harada S-I, Rodan GA. Control of osteoblast function and control of bone mass. Nature 2003;423:349-355.
14. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood RJ. Effects of a bisphosphonate on experimental periodontitis in monkeys. Periodontol 1992;63:825-830.
15. Cumming SR, Black DM, Thompson DE. Randomized trials of the effect of alendronate on the risk of fractures in women with low bone density but without vertebral fractures: Results from the fracture intervention trial. JAMA 1998;280:2077-2082.
16. Jeffcoat MK, Cizza G, Shi WJ, Lombardi A. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis J Int Acad Periodontol (in press).
17. Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: Evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z (ed). The biologic Mechanism of Tooth Resorption and Replacement by Implants. Boston: Harvard Society for the Advancement of Orthodontics, 1996:365-373.
18. El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis. J Int Acad Periodontol 2003;5:5-10.
19. Lane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12-month, randomized, placebo-controlled study. J Periodontol 2005;76:1113-1122.
20. Rizzoli R, Greenspan SL, Bone G III, et al. Alendronate once-weekly study group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-1996.
21. Rocha M, Nava LE, Vazquez de la Torre C, et al. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo-controlled trial. J Periodontol 2001;72:204-209.
22. Rocha ML, Malacara JM, Sánchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: A randomized placebo-controlled trial. J Periodontol 2004;75:1579-1585.
23. Yemm R. Analysis of patients referred over a period of five years to a teaching hospital consultant service in dental prosthetics. Br Dent J 1985;159:304-306.